Skip to main content
. 2018 Jun 14;155(2):238–250. doi: 10.1111/imm.12954

Figure 6.

Figure 6

Combination ImmTAC‐NYE with anti‐programmed cell death protein 1 (PD‐1) monoclonal antibody (mAb) produced synergistic tumour cell killing in vitro for lung cancer patients. (a) Comparison of the PD‐1 expression level of CD4+ T cells in the peripheral blood between healthy donors (n = 29) and lung cancer patients (n = 29). P value was calculated using unpaired Student's t‐test. Significance is indicated as *P < 0·05, ***P < 0·001. (b, c) The anti‐PD‐1 mAb enhanced the ImmTAC‐NYE‐redirected cell killing in lung cancer patients and healthy donors. The peripheral blood mononuclear cells (PBMCs) (1 × 105/well) were cultured for 24 hr with NCI‐H1299 (2 × 104/well) cells at a 5 : 1 effector to target ratio in the presence of ImmTAC‐NYE (10−9 m) and anti‐PD‐1 mAb (10 μg/ml) was added or not. The co‐culture system without ImmTAC‐NYE was used as negative control. Lactate dehydrogenase release was detected for lung cancer patients (b) or healthy donors (c). Unpaired Student's t‐test, **P < 0·01, NS P > 0·05.